Is it time to increase the liposomal doxorubicin dosage for frontline therapy in young adults and adults with classic Hodgkin lymphoma? Comment on: “Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?”

Key Points

• The aim is to evaluate whether an increase in liposomal doxorubicin dosage is beneficial for young adults and adults with classic Hodgkin lymphoma.
• Review of current literature regarding doxorubicin dosage in Hodgkin lymphoma therapy.
• Comparison of outcomes from varying dosage strategies.
• Potential positive impact on treatment effectiveness with higher dosages.
• Concerns regarding toxicity and side effects that need to be balanced against benefits.